6/12/2012 9:02:48 AM
Incoming Boston Scientific CEO Michael Mahoney details the med-tech titan's 2012-2013 development and regulatory approval timelines for its up-and-coming business regions, including for its newly acquired Cameron Health subcutaneous implantable defibrillators and its bronchial thermoplasty business. Boston Scientific's (NYSE:BSX) got a busy road ahead, with regulatory approvals and market launches in the works for products in some of its hottest business divisions. During a conference held in Marlborough, Mass., today, incoming CEO Michael Mahoney – currently listed as president – detailed the outlook for 7 of the company's up-and-coming divisions, including for the newly acquired Cameron Health subcutaneous ICD and the highly competitive renal denervation market.
comments powered by